These included amplification of BRAF and MYC, as well as deletion of FAM46C and CDKN2C, which are well-described oncogenes and tumor suppressors, respectively, that are implicated in MM pathology (Fig. S15B, C). Here, BRAF is linked to Miyoshi myopathy.